C5b-9, Rat, mAb 2A1

Monoclonal antibody 2A1 for detection of rat C5b-9/TCC.

The monoclonal antibody 2A1 recognizes rat C5b-9 (TCC) and competes with human C9 antibodies for the C5b-9 epitope. Therefore, this implies that the reactive epitope is located on the C9 molecule.

In serum, five precursor molecules cooperate to assemble C5b-9 membrane attack complexes. First, C5 convertase cleaves C5, forming C5b, which then triggers C5b-9 complex formation. Subsequently, in the final step, C9 polymerizes, enabling the complex to insert into the cell membrane. Simultaneously, during C5b-8 formation and C9 polymerization, specific neoantigens emerge that are not present on native complex components.

To control this process, complement proteins such as CD59 and complement S-protein actively prevent C5b-9 from inserting into the cell membrane. Hence, the SC5b-9 complex remains cytolytically inactive and is unable to adhere to cells. Importantly, C5b-9 is crucial in chronic proteinuric renal disease by constantly driving tubulointerstitial damage. Therefore, reducing C5b-9 formation can significantly mitigate early tubulointerstitial injury in the remnant kidney.

To address this, the monoclonal antibody 2A1 was specifically developed against a rat C5b-9 neoantigen. Due to its specificity, this antibody serves as a reliable antibody for detecting C5b-9 in plasma and urine samples.

You may also find monoclonal antibody HM3034 clone 3G11, which recognizes rat C6, to be of interest.